Chief Operating Officer...
Chief Operating Officer, Vital Statistics Consulting
Co-Owner & COO, Unbiased Science; Head of Global Medical Information, Recordati Rare Disease Michelle is a scientist, healthcare professional, and executive with over 20 years of experience in healthcare, pharma, biotech, and public health. She specializes in health science communications, digital and AI transformation, patient and HCP engagement, and strategic consulting, including M&A support. As Vice President Elect of Medical Information Leaders in Europe (MILE), Michelle shapes industry best practices, builds future-facing technology, and enhances access to medical information and professional education. She brings diverse expertise as a biologist, critical care nurse, pharmacy technician, and medical toxicology postgraduate, driving innovative solutions that improve operational excellence and patient outcomes.She also serves on the scientific boards of multiple tech and medical companies and leads women-led organizations Unbiased Science and Vital Statistics Consulting.
Founder and Chief Executive Officer...
Founder and Chief Executive Officer, Singleron Biotechnologies
Nan Fang is a Strategic UX/UI Design Lead at Proverb Agency, specializing in creating user-centered digital experiences. With a strong background in design, she leads initiatives that align with business goals while enhancing user satisfaction. Her work emphasizes collaboration, innovation, and a deep understanding of user needs to deliver impactful digital solutions.
Senior Consultant, Abaye Consulting
Ijeoma is a strategic leader at the intersection of clinical innovation and ethical technology, currently serving as a Senior Consultant at Abaye Consulting. With a focus on high-value thought leadership, she specializes in developing inclusive clinical trial designs, sponsor lifecycle automation, and robust ethical AI governance frameworks for the pharmaceutical industry. Her work is dedicated to bridging the gap between advanced algorithms and human-centric healthcare, ensuring that digital transformation in pharma remains both equitable and efficient. A frequent contributor to global summits, Ijeoma provides strategic depth to complex discussions on pharmacovigilance reimagined and the future of smart trials. She is committed to advancing industry standards through automation frameworks that prioritize safety, transparency, and patient-inclusive outcomes.
Advisor, ekwithree
Dr. Dobmeyer co-founded PharmaLex GmbH, transforming it from a consulting startup into a global enterprise operating in 30 countries with 3,000 employees. He completed nearly 40 mergers & acquisitions under his leadership. With a doctorate from the University of Mainz and postgraduate studies in Clinical Evaluation from the University of Marburg, he has held research leadership roles in hematology, oncology, rheumatology, infectiology, and clinical immunology. He now advises and speaks on entrepreneurship, investment strategies, and the future of clinical trials.
Global Capability Owner (GCO)...
Global Capability Owner (GCO)- Customer Targeting & Engagement Planning, Boehringer Ingelheim
With over three decades of extensive international experience in the pharmaceutical industry, Ashish Saxena has held diverse leadership roles across Sales, Training, Sales Force Effectiveness, Commercial Excellence, Digital Transformation, Market Research and Analytics. His career encompasses both operational execution and strategic leadership, fostering a comprehensive and multidimensional expertise in pharmaceutical business complex landscape. Currently based in Germany, Ashish works as the Global Capability Owner at Boehringer Ingelheim, where he leads the global function for Customer Targeting and Engagement Planning. In this role, he is responsible for shaping the global vision and strategy, collaborating with regional and country teams worldwide. He spearheads cross-functional initiatives to develop frameworks, processes, and tools that enable effective segmentation, targeting, and engagement of healthcare professionals (HCPs) and healthcare organizations (HCOs), ensuring alignment with evolving healthcare landscapes and the dynamic business environment.
Lifesciences & Pharma Business Leader
Lifesciences & Pharma Business Leader
Gurpreet Singh was the Vice President, Managing Director Integrated Safety at IQVIA. He is based in UK and has a total of 18 years' experience in Pharma Industry of which 16+ years have been in Global Drug Development. During these years he has had the opportunity to work with some top Global companies like Cognizant, Tata Consultancy, Novartis and Parexel. At Novartis he was the Global Head of PV Operations managing all Global PV activities. At Parexel he was the Senior Director PV Operations responsible for managing PV projects of top Global Pharma and Biotech companies. Gurpreet is a certified Six Sigma and Project Management Professional. He has keen interest in Digital Transformation and Organization Culture and has successfully led various projects during his tenure in the Pharma Industry. He is an avid runner and a speaker at various Pharma conferences.
Founder & Chief Executive Officer...
Founder & Chief Executive Officer, pRxEngage
Keith Berelowitz is the Founder & CEO of pRxEngage Inc. and a long-standing clinical research professional with over 20 years’ experience across trial operations, ethics, and patient engagement. Keith also chairs one of the UK's National Research Ethics Committee and has reviewed thousands of clinical protocols. Keith focuses on improving how people find, understand, and stay engaged with clinical trials by applying behavioural science, plain-language design, and community-led approaches. He is a frequent speaker on trust, clarity, and real-world feasibility in clinical research.
PhD, MBA, CSSBB Founder...
PhD, MBA, CSSBB Founder of BiotechNmed Launch Lab incubator
Dr. Maryam Alavi is a scientist-entrepreneur bridging pharmaceutical rigor and consumer health innovation. With over 18 years of experience spanning regenerative medicine, cancer research, and commercial product development, she brings a unique perspective to the rapidly evolving cosmeceutical and consumer wellness space. Trained at Harvard Medical School, Stony Brook University Hospitals, and the University of Nevada, Reno, Dr. Alavi's career demonstrates her ability to translate complex science into market-ready solutions. She has successfully brought three products to market and transitioned from Research Scientist to Director of R&D, and later to Director of Sales—giving her end-to-end understanding of the product development lifecycle. Dr. Alavi has served as a strategic liaison between technology companies and leading pharmaceuticals, integrating AI/ML and advanced analytics into drug discovery, development, and biomanufacturing. She has built and implemented AI-powered prediction models that optimize workflows in cell and gene therapy, reducing development costs while increasing therapeutic precision.
Principal/Founder, NewtonBio...
Principal/Founder, NewtonBio Consulting
Jon is a Clinical Innovation and Health Tech Strategist in the Life Sciences sector with deep expertise in clinical trial operations, corporate development, and data asset strategy. A seasoned executive who brings a practical understanding of how AI is reshaping healthcare and clinical research—speaking regularly on the intersection of pharmaceutical development, technology, innovation, and strategy with a focus on driving access, efficiency, and impact.
Vice President, Frost & Sullivan
Vice President, Frost & Sullivan
Unmesh Lal brings over 20 years of experience in healthcare strategy and consulting, with a focus on global life sciences and precision health. He specializes in identifying transformative technologies, innovative business models, and growth opportunities across pharmaceutical contract services. A recognized thought leader, Unmesh has authored key industry insights and presented at leading global events including J.P. Morgan, Bio-Asia, and Bio-IT World. He holds a master’s degree in biomedical engineering from the University of Michigan–Ann Arbor.
CEO, Co- Founder, Sarah Jones Coaching
CEO , Co- Founder , Sarah Jones Coaching
Sarah Jones is an Executive & Team Coach specialising in leadership development across the pharmaceutical, biotech, and life sciences sectors. Before founding Sarah Jones Coaching, she led UK, EMEA, and global Corporate Affairs and Patient Advocacy for organisations including Abbott, Johnson & Johnson, and the NHS. She now works with senior leaders and leadership teams across pharma and biotech to help them step out of the technical detail and lead with strategic influence and impact. A long-standing member with the Healthcare Businesswomen’s Association, Sarah has served as a global programme leader and advisor, coaching many of its members worldwide.
Board Chair & Non – Executive Director...
Board Chair & Non – Executive Director , Suzie Harvey Consulting
Board Chair, Non-Executive Director and NHS Governor, Suzie works with CEOs, Chairs and boards to achieve clarity in strategy, confidence in governance and results in international growth. With experience across Life Sciences, HealthTech and AI, she helps leadership teams scale with discipline and resilience. Chairing boards at Evidence to Impact and Nordic AI and advising LabShare.AI, She has strengthened governance, driven revenue growth and supported investment readiness. Drawing on a global commercial career at Signant Health and Qiagen, She bring a clear, collaborative and commercially focused perspective - enabling organisations to govern well and grow with purpose.
CEO, Co-Founder, DaltonTx
CEO, Co-Founder, DaltonTx
CEO and co-founder of DaltonTx, building the platform that will enable the pharma industry to bring more efficacious medicines to patients faster through the use of AI. Before founding DaltonTx I was CTO at Exscientia, leading the teams to build their technology platforms and the Milton Park automated lab. Earlier, three decades at AstraZeneca directing hit discovery and global chemistry strategy.
CEO, Newal R&D Ltd
CEO, Newal R&D Ltd
Dr Rupert Holms ( Ph.D. molecular biology, Edinburgh, Scotland) is CEO of London-based NewalR&D Ltd which is developing the ezrin peptide immune-therapeutic platform for world markets with a focus on respiratory infection, sex infection and mosquito vector viral infection. Dr Holms has expertise in launching life science start-ups including hVIVO PLC in London and Nearmedic Group, a 120million Euro turnover profitable pharmaceutical company in Moscow, Russia. Dr Holms invented the ezrin peptide platform in 1993 and launched the first ezrin peptide product on the Russian market in 2001. Prior to his 35 year career as an entrepreneur, Dr Holms was a life science investment manager at Lombard Odier.
EMBA, MD, PhD, Former ICU Head...
EMBA, MD, PhD, Former ICU Head, CEO, CSO SERENITE-Forceville
Dr Xavier Forceville, French MD, PhD, EMBA, former Head of ICU, Anesthesiologist, Intensivist, Nutritionist, member of INSERM CIC1414, Clinical Investigation Center of Rennes University Hospital, with research interests focusing on infection since 1989, and since 1994 on selenocompounds (e.g. selenoprotein-P, Na-selenite) and selenium in the early diagnosis and treatment of sepsis. Scientific researcher in the biochemical approach of sepsis combining ICU experience (40 years Hospital practitioner) and biochemical expertise (30 years) acquired thanks to extensive informal networks with internationally recognized scientific biochemical teams and thesis.
Global Marketing Director, IPSEN
Global Marketing Director, IPSEN
Simone is a Global Marketing Director with extensive experience in sales, people management, and analytics. Currently at IPSEN Global, he leads marketing strategies for Oncology, launching in new indications and spearheading cross functional Teams. Previously, he was based in Italy, holding key roles at Johnson&Johnson EMEA, driving brand strategies in Hematology and leading digital transformation projects. Simone began his career at Italfarmaco, focusing himself on sales and management. He holds an MBA from SDA Bocconi and an MSc in Chemistry and Pharmaceutical Technologies.
Co-founder & Partner UK Office, ÄHDUS TECHNOLOGY LTD
Co-founder & Partner UK Office, ÄHDUS TECHNOLOGY LTD
Sorbi Khattak is the UK Office Partner and Co-Founder at Ahdus Technology, a software development company focused on building innovative solutions for the healthcare sector. With a background in pharmacy, she contributes clinical insight to technology designed to improve healthcare systems and patient outcomes..
Senior Director Business Development...
Senior Director Business Development , Medable
Sam Fieldwick is Senior Director of Agent Partnerships at Medable, where he leads partnerships for AI agents in clinical development. Sam brings nearly a decade of experience selling technology to the life sciences industry, with roles spanning competitive intelligence at Beacon Targeted Therapies, pharmacovigilance SaaS at ArisGlobal, and AI-powered knowledge graphs and GenAI at Causaly. Across each chapter he's partnered with C-suite and R&D leaders at top pharma and biotech companies to transform emerging technology into practical tools to be used across thousands of scientists in drug development. At Medable, he's channeling that experience into helping sponsors adopt compliant, high-impact AI agents across the clinical trial lifecycle.
Founder & CEO, Anavoq
Founder & CEO, Anavoq
Badri Wadawadigi is a C-suite executive with over 20 years of experience bridging pharmaceutical strategy, M&A, and digital transformation. Currently, he is the Founder and CEO of Anavoq, an AI-driven B2B SaaS platform for life sciences, and leads Sinteza, a specialist health-tech advisory firm. Previously serving as Chief Information & Corporate Development Officer at Pharmanovia and AVP at Accord Healthcare, Badri has led global digital strategies, AI implementation, and complex cross-border transactions. With a background in investment banking at UBS and Jefferies, he brings deep expertise in deal-making, commercial innovation, and operational excellence to the industry.
Founder, Read It to Me
Founder, Read It to Me
Prof. Ashley George PhD, FRSC is an old and cynical chemist who has spent much of his career in the global biopharmaceutical industry, from leading Scientific programmes, through VC-backed biotech start-ups, through to founding 3 US incorporated global Not-For-Profits, both 501C3, & C6s, including The Pistoia Alliance & TechForGood. For 10 years up to 2018, Ashley led GlaxoSmithKline Global Innovation and Consumerisation Centre of Excellence, including digital medical device product launches, global Due-diligences, M&A, global business transformations across Research & Development, Manufacturing Supply chain, Sales and Marketing, for both Pharmaceuticals, FMCG, Consumer health care, Vaccines and internal employees. In 2018, Ashley was lucky enough to be placed on “gardening leave”. As such, he had the opportunity to reflect on 23 years or so of Pharma & Lifesciences global “transformations” and take a long, harsh, stark, cynical- chemist’s retrospective, of all those career trials and tribulations. • Ashley now has developed a global portfolio career advising organisations from FTSE 100, Fortune 500 to global startups both for profit and in the not-for-profit 3rd sector including being President of TechForGood.org which is aligned to the UN SDGs. He is also an FCA trained Investment Banker, a visiting Professor at University College London, and Founder of Read It To Me, RITM, a company that is staffed by battle-hardened, pragmatic technologists who are looking to “leave a legacy” rather than “build a unicorn”, RITM is looking to pragmatically transform direct to patient health literacy across the planet, imagine connecting and engaging, with health content, irrespective of your language, accent, level of literacy or digital accessibility. Examples, include vaccination literacy, strip medicine dispensing and also the cascade of health literacy across East Africa, for diseases such as, Ebola, Marburg & Cholera.
Principal Consultant- Life Science...
Principal Consultant- Life Science, WePhlan
Founder of WePhlan, an AI-powered pharma consulting and solutions company, Fouad brings 20 years of experience in pharmaceutical commercial strategy and operational execution. His expertise spans brand strategy, marketing, launch planning, and AI applications in pharma. He has held multiple global commercial roles at Pfizer and Abbott. Fouad focuses on integrating AI into commercial strategy, launch, and marketing to help pharma organizations strengthen planning, enhance decision-making, and scale execution. He is also the author of the Pharma AI Insider newsletter.
Founder and CEO, INDICRO
Founder and CEO, INDICRO
Trish Parry is founder and CEO of INDICRO Ltd., an award-winning consultancy and business community specialising in Clinical research and training. During her 35 years in clinical research, she has held international operational and strategic roles ranging from CRA to Director of Clinical Operations and has been an independent consultant for 22 years. Trish was a Clinical Subject Matter Expert in the Vaccines Taskforce (now the COVID Vaccines Unit) in UKHSA during the COVID pandemic. Trish has developed and delivered many Transcelerate accredited courses and workshops on Good Clinical Practice to sponsors, investigators and universities. Trish also develops bespoke workshops and mentoring programmes in monitoring, advanced monitoring, clinical project management, vendor management, trial master file management and inspection readiness for clients. Many of the courses have been delivered internationally, in Europe, Turkey, Singapore and Dubai. Trish is author of Statistics in Clinical Research (The Institute of Clinical Research, 2004) and was on the Editorial Board of the Institute of Clinical Research’s Journal, CRFocus from 2005-2014. Trish is one of the founders of the Institute of Clinical Research Trainers Forum, is a committee member of Institute of Clinical Research Ethics and GCP Forum and a Sub-Leader for the UK Clinical Trials Talent Taskforce (CTTT). She is a member of Bioindustry Association (BIA), One Nucleus, OBN Network, and the UK based Independent Clinical Research Freelance Network (ICRFN).
Associate director, real world evidence, Takeda
SVP WW Head of Medical Hematology...
SVP WW Head of Medical Hematology, Bristol Myers Squibb
Ridwaan is the Senior Vice President and Head of Worldwide Medical Affairs Hematology at Bristol Myers Squibb. With more than 27 years of pharma industry experience ( at GSK, JNJ & MSD), Ridwaan has a solid track record of delivery in Oncology & Hematology drug development, medical affairs & brand strategy, leading to successful product launches, optimal lifecycle management including positive outcomes in regulatory engagement & reimbursement negotiations across healthcare systems in the US, Europe, and emerging markets. Ridwaan is a clinical oncologist by training; qualifying as a medical doctor and with credentials in pharmacology and an MBA. He has contributed over his career to the clinical development and commercialization of medicines as strategic partner and through leading governance structures and high-performance teams to provide robust asset and portfolio strategies and evidence generation plans of various hematology, oncology, and supportive care products, including biologics, cytotoxics, targeted therapy, small molecules, immunotherapies, Bispecific molecules, Antibody drug conjugtes (ADCs), Protein degraders and CAR-T cell therapies. He has established scientific networks and collaborations with key opinion leaders, medical societies, cooperative groups, and patient advocacy organizations across the world. He is also a visiting Academic senior lecturer at King's College London in the Department of Cancer and Pharmaceutical Sciences as well as at the Nelson Mandela University medical school Ridwaan is driven by the opportunity to optimize early access to treatments and transform outcomes for patients across the world, together with oncology and hematology research and academic communities, with one focus and determination: to always keep patients at the heart of what he does.
Founder of Closing Delta AI and GM ...
Founder of Closing Delta AI and GM of Health at RELAYTO AI
Gaurav Sanganee brings over 20 years of experience in the pharmaceutical industry, having worked with global organisations including GSK, Novartis, and Boehringer Ingelheim. Throughout his career, he has operated at the intersection of commercial strategy, medical engagement, and digital transformation within life sciences. He is currently the General Manager of RELAYTO AI, an AI-powered content experience platform based in San Francisco, focused on transforming how organisations communicate through interactive, data-driven digital experiences. Gaurav is also the Founder of Closing Delta, a media and strategic platform partnering with leading pharma conferences globally. A Chartered Marketer and ABPI-qualified medical representative, he is a recognised content expert in pharma, podcast host, Ashoka Changemakers contributor, and leadership-trained by The Oxford Group. His work centres on bridging innovation, communication, and human-centric leadership to drive meaningful impact across the healthcare ecosystem.
VP of Digitalization, Author...
VP of Digitalization, Author, Stand-up Comedian, Podcast Host
Transformational leader on a mission. No patient should wait for novel treatment due to lack of trust in our organizations or lack of technology adoption. I architect organizations to go with the grain of human behavior to unleash people’s collective potential. Connector of people and ideas in and between organizations. I love building teams, products and solutions from scratch to scale. Developing business strategy and activating competencies to make it happen. Well-developed business sense and full of ideas for growth.
Managing Director, Redbow Consulting Group
Managing Director, Redbow Consulting Group
Jonathan Dancer MBA is Managing Director of Redbow Consulting Group, a dedicated healthcare strategy consultancy. With over 30 years’ experience in the Pharmaceutical Industry, he founded his first consulting firm in 1999. Jonathan is recognised as a leading pharmaceutical strategy specialist and is currently commercialising an innovative multi agentic strategy model GEM-A® with applications in Pharma, humanitarian, and the not-for-profit sectors. Specialising in cohesive team building, he is particularly interested in the application of technology to the human-centric workplace and how AI can accelerate and augment new and existing workflows. With a background in pharmacy, he is an industry judge, Training Lead for the Pharmaceutical Marketing Society and a visiting lecturer in strategy and marketing at Kings College, London.
CEO & Co-Founder, Service Health erx GmbH
Service Health erx GmbH
David Matthaei is CEO and Co-Founder of service.health erx GmbH, a Berlin-based Health-Tech boutique at the forefront of Germany's digital health transformation. Since co-founding the company, he has built a specialised team driving innovation across the healthcare ecosystem, from electronic prescriptions and the electronic patient record to CardLink, which enables patients to redeem prescriptions from anywhere by simply holding their health card to their smartphone. Under his leadership, service.health has grown to serve over 50 clients spanning hospitals, health insurers, pharma and the national health authority gematik, delivering more than 70 projects that are reshaping how healthcare infrastructure operates at scale. service.health's vision: connecting organisations to serve patients.
Managing Partner, Entourage
Managing Partner, Entourage
Dominik M. Aumer is an entrepreneur, investor, and Founder of Entourage, part of a growing group of specialized consulting companies focused on life sciences. The group combines capabilities across regulatory, quality, market access, and technology to form an integrated service platform. He studied Business Administration at Saarland University and brings over 20 years of experience in building, scaling, and developing service-oriented businesses in life sciences. His focus lies on private equity-driven growth strategies, buy-and-build approaches, and the operational scaling of companies, including the integration of AI and technology-enabled solutions. He works closely with investors and management teams to optimize business models and drive sustainable value creation. Dominik M. Aumer is Managing Partner of Entourage and serves as a Board Member of Entourage Switzerland and Italy.
CEO, co-founder, RELAYTO AI
CEO, co-founder, RELAYTO AI
Alex Shevelenko is Co-Founder and CEO of RELAYTO and host of the Experience-focused Leaders podcast. He focuses on marketing, customer and employee experience design, and the future of work shaped by AI and cloud. Before RELAYTO, he worked with SuccessFactors (SAP), Salesforce, Oliver Wyman, and Microsoft, and co-founded Glocal Ex. He holds an MBA from Stanford and BSE and BA degrees from the University of Pennsylvania, where he also supported research for the Dean of Wharton. His work has earned 60+ awards in digital experience and communications. He is the author of the upcoming book The Experience Is The Message.
Selina Gaertner Consulting
Selina Gaertner Consulting
Selina Gaertner is a TÜV Rheinland-certified AI Strategy Consultant driving Commercial Excellence in Life Sciences, MedTech and Pharma. With extensive experience in Sales, Marketing, and Medical Affairs, she specializes in translating complex AI technology into compliant, high-impact business results. Selina helps leaders navigate the EU AI Act and MDR/IVDR, transitioning teams from unregulated "Shadow AI" to structured, autonomous "Agent Families." Her pragmatic, execution-focused approach ensures AI is a strategic engine that shortens sales cycles and stabilizes pipelines. By bridging the gap between technology and regulation, she secures market leadership for the future of Pharma 2030.
Managing Partner/ Consultant, GreyRigge Associates Limited
Managing Partner/ Consultant, GreyRigge Associates Limited
Samantha is a Managing Partner and Director at GreyRigge Associates with more than 20 years’ experience in the biopharmaceutical industry, including roles at GSK, Ipsen Biopharma, Lonza, and Emergent BioSolutions and the UK Vaccine Task Force. She specialises in CMC strategy, method analytical development, method qualification and validation, and the design and management of complex assay programmes for vaccines, biologics and biosimilars. Samantha also leads product stability study design, and shelf-life modelling and analytical strategy for regulatory submissions across Europe, the USA and China. With deep expertise in Quality by Design, statistical analysis, and CMC project management, she provides tailored, high-quality analytical and outsourcing solutions for global development programmes.
Senior Vice President, Frost & Sullivan
Senior Vice President, Frost & Sullivan
Dinesh Rangaraj is Senior Vice President and Global Practice Lead for Healthcare & Life Sciences at Frost & Sullivan, based in London. With over 25 years’ experience in strategy consulting, business development and operations, he advises global organisations on growth, commercial, R&D and product development strategy. At Frost & Sullivan, he works closely with cross functional teams, bringing together commercial and technical perspectives to support clear decisions and real-world impact for clients.
VP Product Engineering and AI...
VP Product Engineering and AI Strategy, Vital Signs Ecosystem (Pre-Seed Health Venture) | Strategy Advisor, Red Global
Babita Evans Kumar is an Industry 4.0 and Healthcare 4.0 Transformation Leader, AI Strategist, and author of the Trust Code series, known for driving enterprise-wide transformation across global life sciences organizations. With over 20 years of experience, she has led complex, multi-million-dollar programs spanning R&D, manufacturing, supply chain, and patient-centric ecosystems, working with organizations such as Hewlett Packard Enterprise, GSK, and Roche, alongside leading system integrators and cloud platforms. She specializes in translating Industry 4.0 capabilities including AI, digital twins, and intelligent automation into Healthcare 4.0 outcomes such as precision medicine, real-time patient engagement, and resilient, data-driven operations. As a Technology Leader shaping the Vital Signs Ecosystem, she is advancing a human-centric digital health platform focused on improving patient outcomes, experience, and trust. Babita operates at the intersection of AI, enterprise transformation, and trust, enabling organizations to scale innovation, strengthen resilience, and deliver measurable business and patient value.
Grey Rigge Associates
Grey Rigge Associates
Jim has over 29 years’ experience in the biopharmaceutical industry in a number of wide-ranging roles including bioprocess development, GMP manufacturing, Quality, technical and business operations. He has held senior and executive positions within companies such as Cantab Biopharmaceuticals, Xenova, Abzena and Freeline Therapeutics. Jim has a PhD in microbial physiology and biochemistry and a first degree in biotechnology.
General Practitioner at Priory Gardens Surgery
General Practitioner at Priory Gardens Surgery
Dr. Nasir Hannan is a multifaceted General Practitioner with a focus on clinical research and medical advocacy. Based at Priory Gardens Surgery in Dunstable, they serve as the Practice Research Lead and are a member of the East of England Primary Care Research Leadership Team. Beyond clinical work, they are deeply involved in medical politics, sitting on the Executive Committee for the Bedfordshire and Hertfordshire LMC. Their clinical expertise also extends to private practice at The London General Practice on Harley Street. This diverse portfolio allows them to bridge the gap between frontline primary care, regional research innovation, and national policy.
Founder, ORCHA Health
Founder, ORCHA Health
Liz Ashall payne is the Founder of ORCHA Health and an experienced healthcare and life sciences professional with a strong background in pharmaceutical innovation, strategic collaboration, and industry engagement. With extensive experience working across global healthcare initiatives, she has been actively involved in driving discussions around digital transformation, patient-centric innovation, and emerging trends within the pharmaceutical sector. Known for her collaborative approach and industry insight, Liza brings valuable perspectives on the evolving healthcare landscape, particularly in relation to innovation, partnerships, and future-focused healthcare solutions. Her work reflects a strong commitment to advancing meaningful industry dialogue and supporting initiatives that contribute to improved healthcare outcomes and sustainable growth across the life sciences ecosystem.
Head of Scientific Advisory Board, InstaPill
Head of Scientific Advisory Board, InstaPill
Rosaleen “Rosie” McLaughlin joined InstaPill as Chief of the Scientific Advisory Board, bringing with her an illustrious career shaped by decades of leadership across premier pharmaceutical innovators, including Catalent, GSK and Serb Pharmaceuticals. A distinguished authority in advanced drug delivery, Rosie is celebrated for her pioneering contribution to the evolution of oral lyophilisate platforms. Her rare blend of scientific rigour and visionary flair has consistently transformed innovation into meaningful commercial impact. At InstaPill, she assumes stewardship of the company’s scientific agenda, elegantly guiding strategic direction, nurturing portfolio excellence, and championing the next generation of patient-centric, breakthrough therapies with precision and purpose.
Associate Partner, Wavestone, UK, London
Manager, Wavestone, UK, London
👋 Welcome to the 4th Global Pharma Tech Summit 2026!
🙏 Welcome to Pharma Tech London
May 18–19, 2026 | London, UK
Would you like to know details about:
• Sponsorship opportunities
• Available speaking opportunities
• Networking & insights
• Book a quick call
• Agenda request
• Discounts available ️
Click below to start chatting with us on WhatsApp 👇
